FIC Capital’s Nektar Therapeutics NKTR Stock Holding History

FIC Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$2.05M	Buy	5,704 +521	+10%	+$163K	0.78%	43
2017 Q2	$1.52M	Buy	5,183 +652	+14%	+$188K	0.63%	50
2017 Q1	$1.59M	Buy	+4,531	New	+$1.02M	0.71%	47
2016 Q1	–	Sell	-4,857	Closed	-$1.23M	–	124
2015 Q4	$1.23M	Sell	4,857 -4,319	-47%	-$888K	0.54%	54
2015 Q3	$1.51M	Sell	9,176 -67	-0.7%	-$11.9K	0.71%	45
2015 Q2	$1.73M	Sell	9,243 -483	-5%	-$83.1K	0.69%	45
2015 Q1	$1.6M	Sell	9,726 -89	-0.9%	-$18.3K	0.61%	54
2014 Q4	$2.28M	Sell	9,815 -5	-0.1%	-$1.07K	0.88%	34
2014 Q3	$1.78M	Buy	9,820 +374	+4%	+$71.6K	0.71%	49
2014 Q2	$1.82M	Sell	9,446 -612	-6%	-$108K	0.71%	50
2014 Q1	$1.83M	Buy	10,058 +883	+10%	+$175K	0.75%	45
2013 Q4	$1.56M	Buy	9,175 +155	+2%	+$25K	0.7%	46
2013 Q3	$1.41M	Buy	9,020 +3,591	+66%	+$664K	0.72%	51
2013 Q2	$940K	Buy	+5,429	New	+$833K	0.6%	61

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

FIC Capital's NKTR Position: Q3 2017 in Review

FIC Capital increased its Nektar Therapeutics (NKTR) stake by 10% in Q3 2017, buying an estimated $163K and bringing the position to 5,704 shares worth $2.05M. The position accounts for 0.78% of the portfolio, ranked #43.

FIC Capital first reported a position in NKTR in Q2 2013 and has held it in 14 quarters since. The position peaked at $2.28M in Q4 2014. 203 funds tracked by Wall St. Rank hold NKTR as of Q3 2017.

FIC Capital held 5,704 shares of Nektar Therapeutics worth $2.05M as of Q3 2017.
FIC Capital bought 521 Nektar Therapeutics shares in Q3 2017, an estimated $163K.
Nektar Therapeutics made up 0.78% of FIC Capital's portfolio in Q3 2017, its #43 holding.
FIC Capital first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 14 quarters since.
FIC Capital's Nektar Therapeutics position peaked at $2.28M in Q4 2014.
203 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2017.

Based on FIC Capital's 13F filing for Q3 2017, filed 14 Nov 2017.